布里斯托尔·迈尔斯·斯奎布的《Sotyktu》显示,在口服关节炎试验中取得了重大成功,扩大了使用范围。 Bristol Myers Squibb's Sotyktu shows major success in psoriatic arthritis trials, eyeing expanded use.

Bristol Myers Squibb的药物Sotyktu在治疗关节炎的第三阶段试验中取得了显著成功,病人比安慰剂患者有所改善。 Bristol Myers Squibb's drug Sotyktu has shown significant success in Phase 3 trials for treating psoriatic arthritis, with patients demonstrating better improvements compared to those on a placebo. 这种已被批准用于中度至重度斑块性牛皮的药物在2024年前9个月销量增加了52%,达到1.63亿美元. The drug, already approved for moderate-to-severe plaque psoriasis, saw a 52% sales increase to $163 million in the first nine months of 2024. 预计取得的积极结果将导致与卫生当局讨论扩大使用范围的问题。 The positive results are expected to lead to discussions with health authorities for expanded use.